Its most advanced gene expression signatures are for infectious disease diagnostics and are aimed at enabling the appropriate prescription of antiviral and antibiotic medications.
During the year, the growing threat of antimicrobial resistance drove development and adoption of advanced diagnostic tests, including molecular testing.
Some researchers believe that the use of microfluidics in the analysis of exosomes will help clinicians overcome the problem of heterogeneity in cancer cells.
In an initial study, they tested an algorithm based on measurements of IgG and IgM antibodies and levels of C1q, to identify the risk of a patient developing lupus.
As a clinical study seeks to decide whether low levels of PCT can guide antibiotic therapy, researchers are exploring alternate, gene expression biomarkers.
One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.
A research collaboration involving several universities has yielded a technique that they said isolates exosomes from biological samples more effectively than incumbent methods.
A proof-of-concept assay that uses an inkjet-printed nanoscale film achieved performance comparable to that of a laboratory ELISA while testing for leptin.
The semifinalists will receive $50,000 each to develop prototypes of their concepts for submission in the second phase of the challenge.
Researchers from the US and UK used a combination of genetic and metabolomics analyses to home in on methylthioadenosine as sepsis biomarker.